Related Experiment Video
Updated: May 11, 2026
07:28
A Method for Evaluating Timeliness and Accuracy of Volitional Motor Responses to Vibrotactile Stimuli
Published on: August 2, 2016
Beyond empiric checkpoint escalation: Insights from KEYVIBE-010
Andrew Knight1, Ryan J Sullivan2
1Mass General Brigham Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Dana Farber Cancer Institute, Boston, MA, USA.
Med (New York, N.Y.)
|May 9, 2026
Summary
The KEYVIBE-010 trial found that combining adjuvant vibostolimab and pembrolizumab did not improve efficacy in high-risk melanoma patients and increased toxicity. This suggests limited benefit for dual checkpoint inhibition in this setting.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Adjuvant therapy is crucial for resected, high-risk melanoma to prevent recurrence.
- Immune checkpoint inhibitors (ICIs) like pembrolizumab have improved outcomes in melanoma.
- Combined ICI strategies are being explored to enhance efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of adjuvant vibostolimab plus pembrolizumab versus pembrolizumab monotherapy in high-risk melanoma.
- To determine if combination ICI therapy offers improved disease-free survival in the adjuvant setting.
Main Methods:
- Phase 3, randomized clinical trial (KEYVIBE-010).
- Patients with resected, high-risk melanoma were randomized to receive either combination ICI or pembrolizumab monotherapy.
- Trial was stopped early due to futility.
Main Results:
- The combination of vibostolimab and pembrolizumab demonstrated higher toxicity compared to pembrolizumab monotherapy.
- No significant improvement in efficacy was observed with the combination therapy.
- The trial was terminated prematurely due to lack of benefit and increased adverse events.
Conclusions:
- Combined adjuvant vibostolimab and pembrolizumab is not superior to pembrolizumab monotherapy for high-risk melanoma.
- The current data suggest a limited role for dual checkpoint inhibition in the adjuvant treatment of resected, high-risk melanoma.
- Vigilant monitoring for toxicity is essential when considering combination immunotherapy strategies.
More Related Videos
Related Concept Videos
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...